Literature DB >> 26740801

Angina treatments and prevention of cardiac events: an appraisal of the evidence.

David E Winchester1, Carl J Pepine2.   

Abstract

Angina pectoris is the symptomatic manifestation of transient myocardial ischaemia. At the most fundamental level, angina arises when myocardial oxygen demand exceeds the ability of the coronary circulation to provide adequate oxygen delivery to maintain normal myocardial metabolic function. In vivo, the balance of oxygen demand and delivery is a complex physiological process that can be altered by a variety of interventions. Lifestyle modification is a cornerstone of cardiovascular disease management, with or without angina. Additional pharmaceutical and physical interventions are usually applied to patients with angina. Mechanisms of action for these interventions include heart rate modulation, vascular smooth muscle relaxation, metabolic manipulation, revascularization, and others. A number of these interventions have overlapping mechanisms that target angina. Additionally, some interventions may directly or indirectly prevent or delay adverse outcomes such as myocardial infarction or death. This review summarizes current evidence for many applied ischaemia treatments documented to modify angina and comments on available evidence relating to improvement in cardiovascular outcomes.

Entities:  

Keywords:  Coronary artery disease; Ischaemic heart disease; Pharmacological therapies; Secondary prevention

Year:  2015        PMID: 26740801      PMCID: PMC4700909          DOI: 10.1093/eurheartj/suv054

Source DB:  PubMed          Journal:  Eur Heart J Suppl        ISSN: 1520-765X            Impact factor:   1.803


  52 in total

1.  Pharmacotherapy: Xanthine oxidase inhibition for relief of angina pectoris.

Authors:  Ranil de Silva; Kim M Fox
Journal:  Nat Rev Cardiol       Date:  2010-11       Impact factor: 32.419

2.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Authors:  Jean-Claude Tardif; Ian Ford; Michal Tendera; Martial G Bourassa; Kim Fox
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

Review 3.  The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials.

Authors:  Song Peng; Min Zhao; Jing Wan; Qi Fang; Dong Fang; Kaiyong Li
Journal:  Int J Cardiol       Date:  2014-10-24       Impact factor: 4.164

4.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

Review 5.  Trimetazidine for stable angina.

Authors:  A Ciapponi; R Pizarro; J Harrison
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

6.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

7.  Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.

Authors:  Giora Weisz; Ramin Farzaneh-Far; Ori Ben-Yehuda; Bernard Debruyne; Gilles Montalescot; Amir Lerman; Ehtisham Mahmud; Karen P Alexander; E Magnus Ohman; Harvey D White; Ann Olmsted; Gennyne A Walker; Gregg W Stone
Journal:  Am Heart J       Date:  2013-10-16       Impact factor: 4.749

Review 8.  Amiodarone: historical development and pharmacologic profile.

Authors:  B N Singh
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

9.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

Review 10.  A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.

Authors:  Michael J Domanski; Heidi Krause-Steinrauf; Barry M Massie; Prakash Deedwania; Dean Follmann; David Kovar; David Murray; Ron Oren; Yves Rosenberg; James Young; Michael Zile; Eric Eichhorn
Journal:  J Card Fail       Date:  2003-10       Impact factor: 5.712

View more
  5 in total

Review 1.  Experimental and early investigational drugs for angina pectoris.

Authors:  Islam Y Elgendy; David E Winchester; Carl J Pepine
Journal:  Expert Opin Investig Drugs       Date:  2016-11-14       Impact factor: 6.206

2.  Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics.

Authors:  Rahul Tyagi; Amarendar Reddy Maddirala; Mostafa Elfawal; Chelsea Fischer; Christina A Bulman; Bruce A Rosa; Xin Gao; Ryan Chugani; Mingzhou Zhou; Jon Helander; Paul J Brindley; Chih-Chung Tseng; Iain R Greig; Judy Sakanari; Scott A Wildman; Raffi Aroian; James W Janetka; Makedonka Mitreva
Journal:  ACS Infect Dis       Date:  2018-05-14       Impact factor: 5.084

Review 3.  Crosstalk between Inflammation and ROCK/MLCK Signaling Pathways in Gastrointestinal Disorders with Intestinal Hyperpermeability.

Authors:  Lijun Du; John J Kim; Jinhua Shen; Ning Dai
Journal:  Gastroenterol Res Pract       Date:  2016-09-26       Impact factor: 2.260

4.  Anxiety Level and Cardiac Autonomic Modulations in Coronary Artery Disease and Cardiac Syndrome X Patients.

Authors:  Mohamed Faisal Lutfi
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

5.  Comparison of functional exercise capacity, quality of life and respiratory and peripheral muscle strength between patients with stable angina and healthy controls.

Authors:  Irem Huzmeli; Aysel-Yildiz Ozer; Oguz Akkus; Nihan Katayıfcı; Fatih Sen; Saadet Ufuk Yurdalan; Mine Gulden Polat
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.